Seroprevalence of SARS-CoV-2 immunoglobulin G in HIV-positive and HIV-negative individuals in KwaZulu-Natal, South Africa
暂无分享,去创建一个
R. Parboosing | K. Govender | P. Moodley | N. Msomi | Aabida Khan | Lilishia Gounder | K. Francois | I. Chetty | Lunga Xaba
[1] T. de Oliveira,et al. Identification of SARS‐CoV‐2 Omicron variant using spike gene target failure and genotyping assays, Gauteng, South Africa, 2021 , 2022, Journal of medical virology.
[2] Xinling Xu,et al. High seroconversion rate after vaccination with mRNA BNT162b2 vaccine against SARS-CoV-2 among people with HIV - but HIV viremia matters? , 2022, AIDS.
[3] J. Blackburn,et al. Performance of the Abbott SARS-CoV-2 IgG serological assay in South African 2 patients , 2022, PloS one.
[4] C. Alloui,et al. Impaired antibody response to COVID-19 vaccination in advanced HIV infection , 2022, AIDS.
[5] S. A. Abdool Karim,et al. Impact of SARS-CoV-2 variants of concern on Covid-19 epidemic in South Africa , 2021, Transactions of the Royal Society of South Africa.
[6] N. Cassim,et al. Sentinel seroprevalence of SARS-CoV-2 in Gauteng Province, South Africa, August - October 2020. , 2021, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.
[7] S. Madhi,et al. Estimated SARS-CoV-2 infection rate and fatality risk in Gauteng Province, South Africa: a population-based seroepidemiological survey , 2021, International journal of epidemiology.
[8] S. Tollman,et al. SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020–March 2021 , 2021, Emerging infectious diseases.
[9] Christine S. Smedley,et al. Difference in mortality among individuals admitted to hospital with COVID-19 during the first and second waves in South Africa: a cohort study , 2021, The Lancet Global Health.
[10] S. Madhi,et al. Asymptomatic COVID-19 in South Africa - implications for the control of transmission. , 2021, Public health action.
[11] S. Letovsky,et al. A population-based analysis of the longevity of SARS-CoV-2 antibody seropositivity in the United States , 2021, EClinicalMedicine.
[12] M. Peluso,et al. SARS-CoV-2 seroprevalence, and IgG concentration and pseudovirus neutralising antibody titres after infection, compared by HIV status: a matched case-control observational study , 2021, The Lancet HIV.
[13] N. Cassim,et al. Sentinel seroprevalence of SARS-CoV-2 in the Gauteng province, South Africa August to October 2020. , 2021, medRxiv.
[14] Á. Soriano,et al. Overview of SARS-CoV-2 infection in adults living with HIV , 2021, The Lancet HIV.
[15] Sergei L. Kosakovsky Pond,et al. Detection of a SARS-CoV-2 variant of concern in South Africa , 2021, Nature.
[16] A. Welte,et al. Prevalence of anti-SARS-CoV-2 antibodies among blood donors in Northern Cape, KwaZulu-Natal, Eastern Cape, and Free State provinces of South Africa in January 2021. , 2021, Research square.
[17] S. Lee,et al. Antibody Responses 8 Months after Asymptomatic or Mild SARS-CoV-2 Infection , 2020, Emerging infectious diseases.
[18] M. Gandhi,et al. The interplay between HIV and COVID-19: summary of the data and responses to date , 2020, Current opinion in HIV and AIDS.
[19] G. Pantaleo,et al. Changes in SARS-CoV-2 Spike versus Nucleoprotein Antibody Responses Impact the Estimates of Infections in Population-Based Seroprevalence Studies , 2020, Journal of Virology.
[20] M. Leeflang,et al. SARS-CoV-2 seroprevalence worldwide: a systematic review and meta-analysis , 2020, Clinical Microbiology and Infection.
[21] A. Giacomelli,et al. Seroprevalence of SARS-CoV-2 significantly varies with age: Preliminary results from a mass population screening , 2020, Journal of Infection.
[22] C. Viboud,et al. Serological evidence of human infection with SARS-CoV-2: a systematic review and meta-analysis , 2020, The Lancet Global Health.
[23] D. Gill,et al. Are we underestimating seroprevalence of SARS-CoV-2? , 2020, BMJ.
[24] G. Alter,et al. The Power of Antibody-Based Surveillance , 2020, The New England journal of medicine.
[25] H. Rees,et al. The role of serological testing in the SARS-CoV-2 outbreak. , 2020, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.
[26] P. Glasziou,et al. Comparison of seroprevalence of SARS-CoV-2 infections with cumulative and imputed COVID-19 cases: Systematic review , 2020, PloS one.
[27] M. Hernán,et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study , 2020, The Lancet.
[28] C. Reed,et al. Seroprevalence of Antibodies to SARS-CoV-2 in Six Sites in the United States, March 23-May 3, 2020 , 2020, medRxiv.
[29] N. Basta,et al. Serodiagnostics for Severe Acute Respiratory Syndrome–Related Coronavirus-2 , 2020, Annals of Internal Medicine.
[30] Christopher Earl,et al. Preexisting and de novo humoral immunity to SARS-CoV-2 in humans , 2020, Science.
[31] J. Wolchok,et al. The many faces of the anti-COVID immune response , 2020, The Journal of experimental medicine.
[32] A. Fauci,et al. B‐cell responses to HIV infection , 2017, Immunological reviews.
[33] Richard E. Joines. South , 2014, Definitions.
[34] K. Zuma,et al. South African National HIV Prevalence, Incidence, Behaviour and Communication Survey, 2017: towards achieving the UNAIDS 90-90-90 targets , 2019 .
[35] K. Sullivan,et al. OpenEpi: Open Source Epidemiologic Statistics for Public Health. Version 2.3.1. , 2013 .